Overview
BofA Securities has increased its price target on Beam Therapeutics Inc. (NASDAQ: BEAM) to $47 from $45 and left its Buy rating unchanged. At the time of the announcement, the stock was trading at $31.26, while analyst target prices on the name span a wide $22 to $80 range. Beam’s shares have risen roughly 70% over the last six months, reflecting growing investor interest in the company’s gene-editing platform.
Drivers cited by BofA
BofA pointed to a series of updates tied to Beam’s liver-targeted in vivo editing platform. Those updates include the introduction of a new program, BEAM-304, aimed at treating phenylketonuria (PKU), and reported progress within the company’s collaboration with Pfizer. The bank said these developments reinforce the long-term value potential of Beam’s underlying technology.
The analyst note also emphasized near-term milestones. Beam is expected to provide updated phase 1/2 data for BEAM-302 and outline next steps for that clinical program in the first quarter of 2026. In addition, BofA described recent FDA alignment on a potential accelerated approval pathway in alpha-1 antitrypsin deficiency (AATD) - an approach that would assess biomarkers over a 12-month window - as a meaningful regulatory development for the company.
Clinical and operational updates
Beam plans to enroll approximately 50 additional patients in its AATD program. To support its clinical efforts, the company announced a non-dilutive capital agreement intended to help fund its pipeline. According to InvestingPro data cited by the analyst, Beam’s balance sheet currently shows more cash than debt, a position that BofA said enhances the company’s financial flexibility.
Valuation and financial context
BofA noted that its revised $47 target reflects Beam’s present cash position and assumptions about forthcoming license revenue. The firm continues to track both the clinical readouts and the company’s funding posture as inputs to its valuation.
Recent earnings and market reaction
Beam reported financial results for the fourth quarter of 2025 and used its earnings call to highlight strategic initiatives and product development progress. Those disclosures prompted a positive market response, according to the reporting, though specific revenue and earnings figures were not provided in the discussion. The commentary around the earnings call was characterized as optimistic, and no analyst upgrades or downgrades were noted in the reports referenced. Beam’s recent clinical, regulatory and financing actions remain under close observation by investors.
Additional resources
For investors seeking a deeper, model-driven look at valuation and prospects, the company’s Pro Research Report is available, along with similar reports covering more than 1,400 other U.S. equities.
Note: The article presents developments and statements as reported; it does not include undisclosed revenue or earnings figures beyond those referenced.